Click on a field for details on how to access that data via Web API, Excel, or CSV File Download.
| Open Price | |
| High Price | |
| Low Price | |
| Close Price | |
| Change | |
| Percent Change | |
| Volume |
| Avg Daily Volume | N/A |
| 52 Week High | N/A |
| 52 Week Low | N/A |
| Target Price | N/A |
| Ticker | BTX/RT:UA |
| Composite Ticker | BTX/RT:US |
| Security Name | Biotime Inc. |
| Type | Tradeable Rights (Units - Jan 2004) |
| Class | BTX-R |
| Currency | USD |
| Round Lot Size | N/A |
| Primary | No |
| Delisted | Yes |
| ETF | No |
| Market Category | Right |
| Market Sector | N/A |
| Exchange Symbol | ^USCOMP |
| Exchange Name | US COMPOSITE |
| Exchange City | N/A |
| Exchange Country | UNITED STATES OF AMERICA |
| Exchange Website | N/A |
| FIGI | BBG002J81T93 |
| Composite FIGI | BBG000JKSF64 |
| Share Class FIGI | BBG001SGSBZ8 |
| FIGI Unique ID | EQ0000000000874804 |
| Dividend | N/A |
| Dividend Rate | N/A |
| Trailing Dividend Yield | N/A |
| 5-year Average Dividend Yield | N/A |
| Dividend Ex Date | N/A |
| Beta | N/A |
| 1-year beta | N/A |
| 3-year beta | N/A |
| 5-year beta | N/A |
| 7-year beta | N/A |
| 10-year beta | N/A |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
